Open AccessPerils in Benzodiazepine Withdrawal: Case Report
Author(s) -
Vicki F. H. Macfarlane,
Laurie Moore
Publication year - 2020
Publication title -
european journal of medical and health sciences
Language(s) - English
Resource type - Journals
ISSN - 2593-8339
DOI - 10.24018/ejmed.2020.2.3.319
Subject(s) - clonazepam , lorazepam , benzodiazepine , obstructive sleep apnea , medicine , withdrawal syndrome , drug withdrawal , anesthesia , intensive care medicine , psychiatry , drug , receptor
The discovery that clonazepam prescribed for the treatment of migraines caused obstructive sleep apnea led to a rapid taper of clonazepam and substitution of lorazepam. Lack of accurate knowledge about the different pharmacokinetics and actions of different benzodiazepines at GABA-A receptors and the risks associated with rapid benzodiazepine withdrawal resulted in the development of the benzodiazepine protracted withdrawal syndrome. Moderately severe disability continued after 2 years. Insufficient knowledge about benzodiazepines and their withdrawal is a serious problem as doctors across the world are under extreme pressure to stop prescribing them but do not have an understanding of the potential perils involved. The pathophysiology of protracted withdrawal syndrome remains poorly understood and there is no recognised treatment. Information about appropriate management of withdrawal and the protracted withdrawal syndrome are available on Professor Ashton’s website at www.benzo.org.uk.